On Tuesday, Upstream Bio (NASDAQ:UPB) received a positive outlook from TD Cowen, as the firm started coverage on the biotech company's stock with a Buy rating. The optimism is based on the promising prospects of Upstream Bio's asthma treatment, verekitug (TSLPR mAb), which is seen as a strong competitor in the market.
TD Cowen highlighted that verekitug has demonstrated rapid, deep, and sustained effects on asthma biomarkers in its Phase 1 trials. The drug is positioned as a "differentiated fast follower" with greater potency and extended dosing intervals compared to Tezspire, a competing drug from Amgen Inc (NASDAQ:AMGN). and AstraZeneca (NASDAQ:AZN).
The ongoing Phase 2 trials for severe asthma and CRSwNP (chronic rhinosinusitis with nasal polyps) are expected to deliver data in the second half of 2025 and 2026, respectively. Additionally, a Phase 2 trial in COPD (chronic obstructive pulmonary disease) is slated to begin in the second half of 2025.
The analyst from TD Cowen expressed confidence in the drug's mechanism of action and its potential to become a blockbuster, which contributed to the decision to initiate coverage with a Buy rating. The firm's outlook for Upstream Bio is based on the current progress and future milestones anticipated for verekitug.
In other recent news, Upstream Bio's lead candidate, verekitug, has been recognized for its potential in treating severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD).
Piper Sandler began coverage on Upstream Bio, assigning an Overweight rating and a price target of $75.00. The firm highlighted the unique mechanism of action of verekitug that targets the TSLP receptor, which has already been validated.
Furthermore, the biologic market opportunity for treatments like verekitug is estimated to be over $7.5 billion, with upcoming clinical milestones expected to further bolster its prospects.
Similarly, JPMorgan (NYSE:JPM) initiated coverage on Upstream Bio, expressing a bullish stance on the company's stock, primarily due to the promising potential of verekitug. The firm set a price target of $38.00 for December 2025, reflecting confidence in Upstream Bio's strategic direction and the anticipated success of verekitug. Phase 2 data for verekitug in treating CRSwNP is anticipated in the second half of 2025, with data for severe asthma expected in the latter half of 2026.
These recent developments underscore the potential of Upstream Bio's verekitug in the biologics market, with both Piper Sandler and JPMorgan expressing confidence in the company's strategic focus and the drug's potential success.
InvestingPro Insights
Recent data from InvestingPro adds context to Upstream Bio's (NASDAQ:UPB) financial position and market performance. The company's market capitalization stands at $1.35 billion, reflecting investor interest in its potential. Despite the promising outlook for verekitug, InvestingPro data shows that Upstream Bio is not currently profitable, with a negative P/E ratio of -24.59 for the last twelve months as of Q2 2024.
An InvestingPro Tip highlights that UPB holds more cash than debt on its balance sheet, which could provide financial flexibility as it advances its clinical trials. This strong cash position aligns with the company's need for resources to fund ongoing research and development, particularly for verekitug's Phase 2 trials.
Another relevant InvestingPro Tip indicates that UPB has seen a strong return over the last month, with a 14.32% price total return. This recent performance may reflect growing investor confidence in the company's pipeline, particularly following TD Cowen's positive coverage initiation.
For investors seeking a more comprehensive analysis, InvestingPro offers 6 additional tips for UPB, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.